PYC Therapeutics Highlights Progress in Its Transformation to a U.S. Clinical-Stage Company and 2021 Corporate Objectives
Share this article Share this article PERTH, Australia and NEW YORK, Feb. 22, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development. "This year we are focused ...
Western Australia Kaggen Ausma Deborah Elson Matthew Deyoung Sahm Nasseri Leo Vartorella Indianj Ophthalmol
Source: prnewswire.com